Evidence map›Paper›PMID 41019488›Full record

ArticleMaterials today. Bio2025

Epileptogenic zone-targeting nanoparticle drug delivery system for antiseizure medication.

Honglu Ping, Qi Zhang, Xiaojie Chen, Yi Wang, Di Wu, Jianhong Wang, Jun Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Honglu PingDepartment of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China.
Qi ZhangZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences and School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Xiaojie ChenZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences and School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Yi WangZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences and School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Di WuZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences and School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Jianhong WangDepartment of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China.
Jun ZhangDepartment of Radiology, Huadong Hospital, State Key Laboratory of Brain Function and Disorders, Fudan University, No. 221 Yan'an West Road, Shanghai, 200040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is a chronic neurological disorder affecting over 65 million people worldwide, characterized by abnormal excessive excitation of neuronal networks. Traditional antiseizure medications (ASMs), such as phenytoin (PHT), have limited therapeutic efficacy due to poor blood-brain barrier (BBB) penetration and off-target toxicity. To address these issues, this study proposes an electrically responsive closed-loop system drug delivery system (DDS) using PHT as a model drug. The system utilizes electro-responsive nanoparticles made from polypyrrole (PPY), which can contract in response to electrical stimulation, allowing for on-demand drug release during epileptic discharges. Additionally, the excessive activation of tryptophan metabolism in people with epilepsy leads to tryptophan (Trp) depletion, promoting its uptake in the epileptogenic zone and creating a "metabolic trapping" effect. Meanwhile, hyaluronic acid (HA) binds to CD44 receptors, enhancing nanoparticle retention at the lesion, thereby creating a "targeted delivery-extended retention" effect. This non-invasive epileptogenic zone-targeting PPY-HA-PHT-Trp DDS may enhance ASM effect and have potential applications in clinical settings.

Indexed as

BiosafetyElectro-responsive drug releaseEpilepsyNano-drug delivery systemPolypyrrole

Identifiers

PMID41019488
PMCPMC12464691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.